Spero Therapeutics, Inc. (SPRO)
1.215
0.00 (0.00%)
USD |
NASDAQ |
Aug 24, 16:00
1.21
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Total Liabilities (Quarterly) : 8.562M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.562M |
| March 31, 2026 | 6.087M |
| December 31, 2025 | 9.898M |
| September 30, 2025 | 27.68M |
| June 30, 2025 | 29.29M |
| March 31, 2025 | 43.90M |
| December 31, 2024 | 64.42M |
| September 30, 2024 | 69.65M |
| June 30, 2024 | 69.38M |
| March 31, 2024 | 71.45M |
| December 31, 2023 | 75.50M |
| September 30, 2023 | 53.40M |
| June 30, 2023 | 44.10M |
| March 31, 2023 | 47.71M |
| December 31, 2022 | 48.87M |
| September 30, 2022 | 31.99M |
| June 30, 2022 | 27.70M |
| March 31, 2022 | 83.36M |
| Date | Value |
|---|---|
| December 31, 2021 | 82.78M |
| September 30, 2021 | 32.80M |
| June 30, 2021 | 29.34M |
| March 31, 2021 | 24.59M |
| December 31, 2020 | 21.41M |
| September 30, 2020 | 24.25M |
| June 30, 2020 | 23.83M |
| March 31, 2020 | 27.47M |
| December 31, 2019 | 31.53M |
| September 30, 2019 | 19.48M |
| June 30, 2019 | 12.82M |
| March 31, 2019 | 11.32M |
| December 31, 2018 | 13.15M |
| September 30, 2018 | 10.57M |
| June 30, 2018 | 6.924M |
| March 31, 2018 | 6.161M |
| December 31, 2017 | 8.522M |
| September 30, 2017 | 7.273M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 45.02M |
| Fortress Biotech, Inc. | 110.63M |
| Kura Oncology, Inc. | 539.36M |
| Legend Biotech Corp. | 521.32M |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 52.77M |
| Shareholders Equity (Quarterly) | 44.20M |
| Debt to Equity Ratio | 0.0462 |
| Current Ratio | 6.121 |
| Net Debt Paydown Yield | 0.30% |